Anti-IFNg Reference Antibody (emapalumab)
Recombinant Antibody
Catalog # APR10560

Specification

Anti-IFNg Reference Antibody (emapalumab) - Product Information

Application	**FC, E, FTA**
Primary Accession	P01579
Reactivity	**Cynomolgus, Human**
Clonality	**Monoclonal**
Isotype	**IgG1**
Calculated MW	**145.68 KDa**

Anti-IFNg Reference Antibody (emapalumab) - Additional Information

Target/Specificity
IFNg

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-IFNg Reference Antibody (emapalumab) - Protein Information

Name IFNG

Function
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:16914093, PubMed:8666937). Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687). Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093). Plays a role

in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937). In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024). Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687). Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559). Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity).

Cellular Location
Secreted.

Tissue Location
Released primarily from activated T lymphocytes.

Anti-IFNg Reference Antibody (emapalumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-IFNg Reference Antibody (emapalumab) - Images

Anti-IFNg Reference Antibody (emapalumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%

The purity of Anti-IFNg Reference Antibody (emapalumab)is more than 99% ,determined by SEC-HPLC.